檢索結果 - Chun-Ming Tsai

Refine Results
  1. 1
    Low copy number and low oxidative damage of mitochondrial DNA are associated with tumor progression in lung cancer tissues after neoadjuvant chemotherapy

    Low copy number and low oxidative damage of mitochondrial DNA are associated with tumor progression in lung cancer tissues after neoadjuvant chemotherapy 由 Chun‐Fu Lin, Lisheng Wang, Chun‐Ming Tsai, Yau‐Huei Wei

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    The effects of pad geometry and material properties on the biomechanical effectiveness of 26 commercially available hip protectors

    The effects of pad geometry and material properties on the biomechanical effectiveness of 26 commercially available hip protectors 由 Andrew C. Laing, Fabio Feldman, Mona Jalili, Chun Ming Tsai, Stephen N. Robinovitch

    出版 2011
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Symptom Clusters and Relationships to Symptom Interference with Daily Life in Taiwanese Lung Cancer Patients

    Symptom Clusters and Relationships to Symptom Interference with Daily Life in Taiwanese Lung Cancer Patients 由 Shu‐Yi Wang, Chun-Ming Tsai, Bing-Chang Chen, Chien‐Huang Lin, Chia‐Chin Lin

    出版 2008
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Effect of walking on circadian rhythms and sleep quality of patients with lung cancer: a randomised controlled trial

    Effect of walking on circadian rhythms and sleep quality of patients with lung cancer: a randomised controlled trial 由 Hui‐Mei Chen, Chun-Ming Tsai, Yu–Chung Wu, Kuan‐Chia Lin, Chia–Chin Lin

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer

    Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer 由 Chi‐Lu Chiang, Yi‐Wei Chen, Mei‐Han Wu, Hsu-Ching Huang, Chun‐Ming Tsai, Chao‐Hua Chiu

    出版 2016
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer

    Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer 由 Massimo Di Maïo, Francesco Perrone, Paolo Chiodini, Ciro Gallo, Carlos Camps, Wolfgang Schuette, Élisabeth Quoix, Chun-Ming Tsai, Cesare Gridelli

    出版 2007
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  7. 7
    Identifying cancer origin using circulating tumor cells

    Identifying cancer origin using circulating tumor cells 由 Si-Hong Lu, Wen‐Sy Tsai, Ying‐Hsu Chang, Teh‐Ying Chou, See‐Tong Pang, Po‐Hung Lin, Chun‐Ming Tsai, Ying Chang

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

    A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) 由 Yuankai Shi, Joseph S. K. Au, Sumitra Thongprasert, Sankar Srinivasan, Chun‐Ming Tsai, Mai Trong Khoa, K. Heeroma, Y. Itoh, Gerardo Cornelio, Pan‐Chyr Yang

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Association between Tumor Epidermal Growth Factor Receptor Mutation and Pulmonary Tuberculosis in Patients with Adenocarcinoma of the Lungs

    Association between Tumor Epidermal Growth Factor Receptor Mutation and Pulmonary Tuberculosis in Patients with Adenocarcinoma of the Lungs 由 Yung‐Hung Luo, Chieh‐Hung Wu, Wen-Shuo Wu, Chu‐Yun Huang, Wei‐Juin Su, Chun‐Ming Tsai, Yu‐Chin Lee, Reury-Perng Perng, Yuh‐Min Chen

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non-small Cell Lung Cancer Patients Aged 70 Years or Older

    Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non-small Cell Lung Cancer Patients Aged 70 Years or Older 由 Yuh-Min Chen, Chun-Ming Tsai, Wen-Chien Fan, Jen-Fu Shih, Shih-Hao Liu, Chieh-Hung Wu, Teh‐Ying Chou, Yu-Chin Lee, Reury-Perng Perng, Jacqueline Whang‐Peng

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies

    Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies 由 Myung‐Ju Ahn, Chun‐Ming Tsai, Frances A. Shepherd, Lyudmila Bazhenova, Lecia V. Sequist, Toyoaki Hida, James Chih‐Hsin Yang, Suresh S. Ramalingam, Tetsuya Mitsudomi, Pasi A. Jänne, Helen Mann, Mireille Cantarini, Glenwood Goss

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer

    First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non... 由 Keunchil Park, Chong‐Jen Yu, Sang-We Kim, Meng-Chih Lin, Virote Sriuranpong, Chun-Ming Tsai, Jong-Seok Lee, Jin Hyoung Kang, K.C. Chan, Pablo Ernesto Pérez, Peter Button, Myung‐Ju Ahn, Tony Mok

    出版 2015
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer

    Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer 由 Yi‐Long Wu, Shun Lü, You Lü, Jianying Zhou, Yuankai Shi, Virote Sriuranpong, Jcm Ho, Byoung Chul Cho, Chun‐Ming Tsai, Chin‐Hee Chung, Keith D. Wilner, Yiyun Tang, Elizabeth T. Masters, Paulina Selaru, Tony Mok

    出版 2018
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

    CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials 由 Glenwood Goss, Chun‐Ming Tsai, Frances A. Shepherd, Myung‐Ju Ahn, Lyudmila Bazhenova, Lucio Crinò, Filippo de Marinis, Enriqueta Felip, Alessandro Morabito, Rachel Hodge, Mireille Cantarini, Martin Johnson, Tetsuya Mitsudomi, Pasi A. Jänne, James Chih‐Hsin Yang

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

    Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial 由 Karen Kelly, Nasser K. Altorki, Wilfried Eberhardt, Mary O’Brien, David R. Spigel, Lucio Crinò, Chun-Ming Tsai, Joo-Hang Kim, Eun Kyung Cho, Philip C. Hoffman, С. В. Орлов, Piotr Serwatowski, Jiuzhou Wang, Margaret A. Foley, Julie D. Horan, Frances A. Shepherd

    出版 2015
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

    Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis 由 Chee Khoon Lee, Chris Brown, Richard J. Gralla, Vera Hirsh, Sumitra Thongprasert, Chun‐Ming Tsai, Eng Huat Tan, Jcm Ho, D. Chu, Adel Zaatar, Jemela Anne Osorio Sanchez, Vu Van Vu, Joseph S. K. Au, Akira Inoue, Siow Ming Lee, Val Gebski, James Chih‐Hsin Yang

    出版 2013
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  17. 17
    P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥65 Years: Subgroup Analysis of LUX-Lung 3/6

    P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥65 Years: Subgroup Analysis of LUX-Lung 3/6 由 Luis Fein, Yi‐Long Wu, Lecia V. Sequist, Sarayut Lucien Geater, Sergey Orlov, Ki Hyeong Lee, Chun‐Ming Tsai, Terufumi Kato, Katsuyuki Kiura, Carlos H. Barrios, Martin Schüler, Vera Hirsh, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Tony Mok, Dan Massey, Angela Märten, James Chih‐Hsin Yang

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

    A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients 由 Giorgio V. Scagliotti, Denis Moro‐Sibilot, Jens Kollmeier, Adolfo Favaretto, Eun Kyung Cho, Heidrun Grosch, Martin Kimmich, Nicolas Girard, Chun-Ming Tsai, Te‐Chun Hsia, Matteo Brighenti, Christian Schumann, Xuejing Aimee Wang, Sameera R. Wijayawardana, Aaron M. Gruver, Johan Wallin, Kambiz Mansouri, Volker Wacheck, Gee‐Chen Chang

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

    Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial 由 James Chih‐Hsin Yang, Jin‐Yuan Shih, Wu‐Chou Su, Te‐Chun Hsia, Chun-Ming Tsai, Sai‐Hong Ignatius Ou, Chong‐Jen Yu, Gee‐Chen Chang, Ching-Liang Ho, Lecia V. Sequist, Arkadiusz Z. Dudek, Mehdi Shahidi, Xiuyu Julie Cong, Robert M. Lorence, Pan‐Chyr Yang, Vincent A. Miller

    出版 2012
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small cell lung cancer

    Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small... 由 Vassiliki A. Papadimitrakopoulou, Ji‐Youn Han, Myung‐Ju Ahn, Suresh S. Ramalingam, Angelo Delmonte, Te‐Chun Hsia, Janessa Laskin, Sang‐We Kim, Yong He, Chun‐Ming Tsai, Toyoaki Hida, Makoto Maemondo, Terufumi Kato, Suzanne Jenkins, S. Patel, Xiangning Huang, Gianluca Laus, Aleksandra Markovets, Kenneth S. Thress, Yi‐Long Wu, Tony Mok

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: